Skip to main content
OpenTrials
Completed

NCT Number: NCT03296046

Epidemiologic Study of Persistent Polyclonal B-cell Lymphocytosis (PPBL)

The main purpose of this study is the description of all French cases of PPBL and the establishment of minimal criteria for the pathology diagnosis and its follow-up.

The secondary objective is the immunologic and genetic characterization of lymphoid cells causing the disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Persistent Polyclonal B-Cell Lymphocytosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

group GFHC and intergroup LLC (GCFLL-MW / GOELAMS), Marseille, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • PPBL diagnosis established during a previous medical visit

Exclusion criteria

  • None

Treatment and study plan

blood test

Biological

30 ml

Primary outcomes

  1. Relevant medical history

    Time frame: Baseline

  2. Complete blood count

    Time frame: Baseline

  3. Administration of first-line treatment or not

    Time frame: Baseline

Secondary outcomes

  1. Lymphocyte phenotype

    Time frame: Baseline

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Epidemiologic Study of Persistent Polyclonal B-cell Lymphocytosis (PPBL) - Observatory 1990-2012

Acronym: LPLB

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
Sep 28, 2017
Registry last updated
Sep 28, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.